Preci-Health Appoints Paul Kirchgraber, MD, MBA as Chairman of the Board

August 13th, 2025 | Neuchâtel, Switzerland

Preci-Health, developer of a groundbreaking needle-free blood collection device, is pleased to announce the appointment of Paul Kirchgraber, MD, MBA, as Chairman of the Board.

Dr. Kirchgraber is a globally recognized leader in clinical diagnostics and laboratory services. He previously served as CEO of Covance, one of the world’s largest contract research organizations (CROs), and later as CEO of Labcorp Drug Development, a Fortune 500 company with $6 billion in annual revenue, running clinical trials across more than 100 countries. With decades of executive leadership at the helm of these industry-defining organizations, Paul brings invaluable expertise to Preci-Health and will also dedicate significant operational time to advancing the company’s strategic and commercial objectives.

Currently, he serves as an Independent Director on the boards of Flagship BioSciences and MLM Medical Labs, and advises private equity firms in the healthcare sector. He chaired the Association of Clinical Research Organizations (ACRO) Board of Directors in 2023, having served on the board since 2019.

“We are thrilled to welcome Paul to Preci-Health as Chairman of the Board,” said Patrick Berdoz, Co-Founder of Preci-Health. “His expertise in clinical trials, laboratory operations, and global healthcare, combined with his deep understanding of the healthcare ecosystem, makes him an invaluable addition to our team.”

Dr. Kirchgraber’s career spans both the U.S. and global healthcare sectors. Before his tenure at Labcorp, he held senior leadership roles at Covance and Quintiles Laboratories, overseeing operations across multiple continents. He holds an MD from Weill-Cornell Medical School, an MBA from SUNY Binghamton, and board certification in anatomic, clinical, and cytopathology.

“Preci-Health is well-positioned to transform blood diagnostics, and I’m excited to join the company at this pivotal stage,” said Dr. Kirchgraber. “I look forward to contributing to the company’s success and its mission to make blood collection safer, simpler, and more accessible.”

About Preci-Health
Preci-Health, a Swiss-based medtech and AI innovator, is redefining the $80 billion in vitro diagnostics (IVD) industry with EZdraw™ — a cutting-edge, needle-free blood sampling solution that eliminates the need for trained phlebotomists. Designed for both at-clinic and at-home use, EZdraw™ offers unparalleled convenience and precision, positioning Preci-Health to offer a superior solution compared to current market offerings and transform remote healthcare.

For inquiries, please contact info@precihealth.com